Asset / Drug

Advancements

Drug and asset intelligence for Advancements with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Stage: Development stage unavailable

Mechanism of action

Immunotherapy

Recent signals(2)

StrategyJune 21, 2026

Advancements in Subcutaneous Drug Delivery for High Concentration Antibody Products

The review discusses the development of patient-centered subcutaneous drug delivery systems for high concentration biologics, emphasizing formulation and device options.

ClinicalJune 19, 2026

Advancements in NK Cell-Based Immunotherapy for Cancer Treatment

NK cell therapies are advancing with promising safety profiles and clinical applicability, leveraging various innovative strategies.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Therapeutic areas

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.